Trending Topic

Acute myeloid leukaemia
3 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

“We are facing an exciting era of fast-paced drug development in acute myeloid leukaemia” writes Gianfranco Bittar and colleagues at Baylor College of Medicine, Houston, TX, USA, in a review published in touchREVIEWS in Oncology & Haematology. In 2020, there were an estimated 21,450 new patients with acute myeloid leukaemia (AML) and 11,180 AML-related deaths […]

3 mins

Advice for early career multiple myeloma specialists – María-Victoria Mateos

María-Victoria Mateos
Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Mar 6th 2023

At touchHAEMATOLOGY we aim to support early career haematologists and oncologists. In this video a global leader in the field of multiple myeloma, María-Victoria Mateos, shares her advice on stating a successful career in this specialty.

Disclosures: María-Victoria Mateos discloses the following –  Advisory Board or panel fees from Abbvie, Adaptive, Amgen, Celgene, GlaxoSmithKline, Genentech, Janssen, Oncopeptides, Pfizer, Regeneron, Roche, Sanofi and Takeda. Speaker’s Bureau fees from Amgen, Celgene, GlaxoSmithKline, Janssen and Takeda.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Nicola Cartridge.

View more multiple myeloma content:

  • Dr María-Victoria Mateos (University of Salamanca, Salamanca, Spain) shares the recent updates in bispecific monoclonal antibodies for patients with refractory/relapsed multiple myeloma . Watch here on touchHAEMATOLOGY
  • Dr Shaji Kumar (Mayo Clinic, MN, USA) discusses the results of some key clinical trials presented at ASH 2022 in the field of older, frail transplant ineligible patients with multiple myeloma. Watch here on touchONCOLOGY
  • Dr Joseph Franz and Dr Sagar Lonial discuss the recent ATLAS study (ClinicalTrials.gov Identifier: NCT02659293) and optimal post-ASCT management in patients with multiple myeloma. Read here on touchONCOLOGY
Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup